Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iruplinalkib in ROS1 Positive NSCLC
NCT06436885Phase 1Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iruplinalkib in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 24 months. Started Feb 2024; status: recruiting.
02
Drugs
iruplinalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06436885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06436885.